SecBot SecBot
8-K ·Filed Nov 6, 2026

NKTX

Nkarta, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed10d 9h ago SEC0001787400-26-000023
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The webcast on November 9 will disclose initial clinical data for NKX019 in autoimmune indications. The data's safety and efficacy profile will determine the next catalyst for the stock.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.59
T+0 close · Nov 6, 2026 · via day close
Latest settled
−23.90%
T+5 · $1.21
Vs SPY
−22.21%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.59entry
  2. T+1 · 7d ago −15.09%α −14.73% · $1.35
  3. T+5 · 18h ago −23.90%α −22.21% · $1.21
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nkarta filed an 8-K announcing a webcast on November 9, 2026 to review initial clinical data for NKX019 in myositis and systemic sclerosis from the Ntrust program, being presented at ACR Convergence 2026. No clinical data or financial results were disclosed in the filing.

Key Facts

  • Webcast scheduled for November 9, 2026 at 8:00 a.m. ET
  • Initial clinical data from Ntrust program evaluating NKX019 in myositis and systemic sclerosis
  • Data being presented at ACR Convergence 2026 in Orlando
  • Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation trials
  • Trials enrolling up to 12 patients per dose level per disease indication
  • Leading indications: myositis and systemic sclerosis; also ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, primary membranous nephropathy

Financial Impact

No financial data disclosed in this filing

Risk Factors

  • No clinical data or financial results in this filing; all material information will come during the November 9 webcast
  • Early-stage clinical data may show safety or efficacy concerns

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001787400-26-000023
Document: nktx-ex99_1.htm0001787400-26-000023
Document: 0001787400-26-000023-index-headers.html0001787400-26-000023
Document: 0001787400-26-000023-index.html0001787400-26-000023
Document: 0001787400-26-000023.txt0001787400-26-000023

Track record

13 reports on NKTX

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Viewing Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026